Fierce Pharma
OCTOBER 1, 2024
Johnson & Johnson is laying off 231 employees in New Jersey and Bayer is cutting 57 positions in the state, according to separate Worker Adjustment and Retraining Notification (WARN)
MedCity News
SEPTEMBER 29, 2024
The Federal Trade Commission has sued CVS Caremark, Express Scripts and Optum Rx, alleging that they engage in “anticompetitive and unfair rebating practices” as it relates to insulin. One legal expert believes the FTC might win this legal battle. The post The FTC Is Suing PBMs Over Insulin Prices. Will It Be Successful? appeared first on MedCity News.
PharmaVoice
OCTOBER 4, 2024
Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.
pharmaphorum
OCTOBER 2, 2024
A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax authorities, allowing a securities-fraud class action to proceed against the pharmaceutical giant.
Speaker: Kevin Burke
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
Fierce Pharma
OCTOBER 4, 2024
After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter International—the U.S.’ top supplier of hospital IV fluids—is laying out det | While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online.
MedCity News
OCTOBER 3, 2024
More investors are becoming interested in digital health startups specifically targeting youth behavioral health. However, there are still more opportunities to reach youth on Medicaid. The post Funding In Youth Mental Health Is Growing. Where are the Opportunities? appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
OCTOBER 4, 2024
Bristol Myers Squibb (BMS) has been granted approval by the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC).
Fierce Pharma
OCTOBER 2, 2024
Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir. | The company will allow six generic manufacturers to make and sell its long-acting PrEP drug, lenacapivir, in 120 resource-limited countries.
MedCity News
SEPTEMBER 30, 2024
In this month’s episode, Senior Reporter Katie Adams explored some of the executive moves, exits and layoffs that recently occurred in the healthcare sector. She also interviewed Dr. Jayne Morgan, who recently became vice president of medical affairs at Hello Heart. The post MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Dr. Jayne Morgan, VP of Medical Affairs at Hello Heart appeared first on MedCity News.
Pharmaceutical Technology
OCTOBER 2, 2024
Exscientia detailed how its robotics lab in Oxfordshire, UK is increasing productivity and efficiency in developing new molecules at ELRIG 2024.
Advertiser: ZoomInfo
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
pharmaphorum
OCTOBER 3, 2024
Gilead has partnered with six generic manufacturers to expand access to HIV Drug lenacapavir in high-incidence, resource-limited countries following promising clinical trial results.
Fierce Pharma
OCTOBER 2, 2024
Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility fkansteiner Wed, 10/02/2024 - 07:31
MedCity News
OCTOBER 3, 2024
The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority. The post First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic appeared first on MedCity News.
Pharmaceutical Commerce
SEPTEMBER 30, 2024
Why looming benefit changes—and the resulting unintended consequences—are a concern for patients.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
pharmaphorum
OCTOBER 3, 2024
Proscia announces launch of Concentriq Embeddings and Proscia AI Toolkit, hoping to accelerate precision medicine R&D.
Fierce Pharma
OCTOBER 3, 2024
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, | Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
MedCity News
OCTOBER 2, 2024
Alpine Physician Partners — which operates primary care organizations in several states — is implementing Ambience Healthcare’s documentation and coding tool after a successful pilot. Before adopting Ambience’s tool, Alpine clinicians spent 4.7 hours on charting per day, but now that time has dropped down to 1.2 hours per day. The post How A Physician Group Is Using AI to Save Clinicians 3+ Hours Per Day on Documentation appeared first on MedCity News.
PharmaTimes
OCTOBER 3, 2024
Phase 1 trial of IRL757 demonstrates good absorption and safety profile
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
OCTOBER 2, 2024
FDA issues summary of grants, promotes rare disease research Nicole.
Fierce Pharma
OCTOBER 3, 2024
On its way to becoming the most highly anticipated approval of 2024, BMS’ schizophrenia treatment Cobenfy has had an unusual but instructive odyssey.
MedCity News
OCTOBER 3, 2024
AI startups should be thoughtful about which healthcare market(s) they’re going after, according to investors at Bessemer Venture Partners. Healthcare AI startups seeking venture capital face heightened expectations for scale, which requires access to substantial total addressable markets. The post How Can AI Startups Navigate Healthcare’s Fragmented Landscape?
PharmaTech
OCTOBER 3, 2024
Pharmaceutical Technology sat down with Erica Schlesinger, vice president of technical development at Serán Bioscience, to talk about her upcoming presentation at AAPS PharmSci 360 2024, “High Dose Subcutaneous Delivery of Protein Therapeutics.
pharmaphorum
SEPTEMBER 30, 2024
Chiesi Biotech Center of Excellence opens to strengthen R&D in Italy Nicole.
Fierce Pharma
OCTOBER 3, 2024
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an
MedCity News
OCTOBER 3, 2024
Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE. The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026. The post CBRE Report: Post-Pandemic Slowdown Now Evident in Oversupply of Biotech Labs appeared first on MedCity News.
Pharmaceutical Technology
OCTOBER 3, 2024
GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.
Advertiser: ZoomInfo
In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.
pharmaphorum
OCTOBER 4, 2024
FDA declares an end to tirzepatide shortage, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.
Fierce Pharma
SEPTEMBER 30, 2024
After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound in 2025. | Ahead of the CPHI conference in Milan, the events group has teased new research signaling an expected rebound for the CDMO industry—and a rejection of the BIOSECURE Act.
MedCity News
OCTOBER 2, 2024
A more measured approach to noncompete clauses can be fair to physicians and provider organizations, and also serve patients better. Here are four elements for a policy on noncompetes that will work for healthcare. The post Forging a Noncompete Policy That Works for Healthcare appeared first on MedCity News.
Pharmaceutical Technology
OCTOBER 2, 2024
The funds will support the development of LoQus23’s lead candidate, its MutSβ inhibitor, as it enters clinical development.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Expert insights. Personalized for you.
318 
Let's personalize your content